You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Noregen(TM), a regenerative medicine ocular therapeutic
SBC: Retinal Solutions LLC Topic: NEIProject Summary Diabetic retinopathy and Retinal Vein OcclusionRVOaccount for most new cases of blindness in the United StatesThese diseases are marked by retinal swellingedemaand new leaky vessel formationneovascularizationtriggered by pathologically high concentrations of Vascular Endothelial Growth FactorVEGFThe primary treatment is VEGF blocking drugs to control the neovascularization and edem ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Nanoparticle-based Intraperitoneal Delivery of Combined Chemo-brachytherapy for Treatment of Ovarian Cancer Metastases
SBC: Nami Therapeutics Corp. Topic: 102PROJECT SUMMARY ABSTRACT Ovarian cancer is the second most common gynecologic cancer in the United States and the most common cause of death among women with gynecologic malignanciesDespite advances in treatment strategiesperitoneal metastasis remains the primary cause of morbidity and mortality in ovarian cancerThe National Cancer Research Institute Clinical and Translational Radiotherapy Researc ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Urocortin-2 Gene Transfer for Type 1 Diabetes and Associated LV Dysfunction
SBC: Renova Therapeutics, Inc. Topic: NHLBIABSTRACT TypeDiabetes MellitusT DMaffectsmillion patients in US withnew patients annuallyLifespan is shortenedyearsdue to kidney and heart diseaseTight glucose control reduces microvascular complications and adverse cardiovascular eventsInsulin therapy is essential for such patientsbut has shortcomingsaonlyinpatients achieve targeted glucose controlHbA c andltbaggressive insulin therapy increases ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
The first commercial rapid diagnostic test to detect Paragonimus infections
SBC: NANOCOMPOSIX, INC. Topic: NIAIDAbstract We propose an ultrasensitive rapid diagnostic testRDTto detect exposure to pulmonary flukes of the genus ParagonimusParagonimiasis affects an estimatedmi l l ion people and remains amongst the most neglected of all neglected tropical diseasesNTDsThis trematode is acquired upon ingestion of raw or undercooked freshwater crustaceans and migrates to the lungs where it forms cystsTreatment is ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Targets of Acquired Tick-Resistance As Anti-Tick Vaccines
SBC: L2 DIAGNOSTICS LLC Topic: NIAIDABSTRACTThis proposal seeks to develop a novel vaccine against pathogens transmitted by the blacklegged tick, Ixodes scapularis, by targeting tick salivary proteins (Salps) critical for tick feeding. I. scapularis Salps provide functions critical for evading host defense responses detrimental to the tick. Further, these salivary functions are also co-opted by tick-transmitted pathogens to ensure t ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Developing an efficient E-cigarette aerosol generation and exposure system for rodent models with aerosol characteristics equivalent to those inhaled by E-cigarette users
SBC: AUTOMATE SCIENTIFIC, INC. Topic: NIDAAbstract E cigarettes (E-cigs) are increasingly popular worldwide, in particular, among youths. E-cigs may contribute to nicotine addiction and are unlikely to discourage conventional cigarette smoking. Mainstream and second-hand E-cig aerosols contain, in addition to nicotine, detectable levels of toxins including carcinogens and heavy metals such as formaldehyde, benzene, nitrosamines, cadmium a ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Targeting lipid rafts for treatment of asthma
SBC: RAFT PHARMACEUTICALS LLC Topic: NIAIDPROJECT SUMMARY Asthma, characterized by airways obstruction with symptoms of wheezing, shortness of breath, chest tightness and consequently cough, remains a significant health problem. While advances in bronchodilator, corticosteroid and Th2-targeting therapy allow for well-controlled asthma in a large population of patients, subjects with severe, corticosteroid resistant asthma require frequent ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Bone Metastasis Specific 18F PET Imaging Probe for Breast Cancer
SBC: BIOVINC, LLC Topic: 102ABSTRACTBreast CancerBCis the leading cause of cancer death for woman in the USBreast cancer is treated by a combination of surgeryradiationand various types of chemo and targeted therapeutic strategiesApproximately half of patients who have positive sentinel lymph nodes at surgeryand as many asof patients who do noteventually present with metastatic diseaseOverof BC patients eventually have skele ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
A Novel Two-in-One Approach to Administer Surfactant and Provide Airway Support to VLBW Infants
SBC: BB MEDICAL SURGICAL, INC. Topic: NICHDPROJECT SUMMARY / ABSTRACT Every year, 50,000 very low birth weight (VLBW, andlt;1,500 g) infants are born in the U.S. The use of surfactant dramatically decreases morbidity and mortality due to respiratory distress syndrome (RDS) in VLBW infants. Current standards for surfactant administration require the infant to be intubated, so that surfactant can be delivered to the trachea and lungs. Intuba ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
NOVO-118 as a therapeutic to promote remyelination in in vivo models of MS
SBC: NOVORON BIOSCIENCE INC Topic: NINDS7. Project Summary Multiple sclerosis (MS) is a neurodegenerative disease in which myelin of the central nervous system (CNS) is destroyed by a self-reactive immune response. This demyelination is accompanied by the death of the myelinating cells themselves, the oligodendrocytes. Repeated bouts of demyelination leave the denuded CNS neurons vulnerable to degradation and is the major cause of neuro ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health